Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Multiple Myeloma News Source Type: news
More News: Cancer & Oncology | Conferences | Dexamethasone | Myeloma | Revlimid | Toxicology | Velcade